What is the cure rate with current therapies? | Harry Janssen, MD, PhD

International Workshop on HBV Cure 2018

Combination treatment of a TLR7 agonist RO7020531 and a core protein allosteric modulator RO7049389 achieved sustainable viral load suppression and HBsAg loss in an AAV-HBV mouse model | Yonghong Zhu

International Workshop on HBV Cure 2018

Establishing functional control of HBV and HDV infection with REP 2139-based combination therapy | Andrew Vaillant

International Workshop on HBV Cure 2018

Clinical update on reducing HBV virus and antigen production using RNAi | Bruce Given

International Workshop on HBV Cure 2018

Clinical update, antiviral effect and mode of action of capsid assembly modulators | Jeysen Yogaratnam

International Workshop on HBV Cure 2018

Session 4 Panel discussion

International Workshop on HBV Cure 2018

Targeting HBV Core Protein to Clear Infection and Achieve Higher Cure Rates | Richard Colonno

International Workshop on HBV Cure 2018

Clinical progress of the entry inhibitor Myrcludex B | Stephan Urban

International Workshop on HBV Cure 2018

Rationale for different Virological Targets in HBV | Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC

International Workshop on HBV Cure 2018

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Update on changes in Hepatitis B and C in CEE countries- Miłosz Parczewski, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Epidemiology of HIV Infection and Treatment in Europe- Teymur Noori, MSc

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Country models: what has and what hasn’t worked- Nikoloz Chkhartishvili, MD, MS, PhD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Country models: what has and what hasn’t worked- Zahedul Islam, MBA

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Hepatitis Delta: what are the new developments, what are the challenges?- Cihan Yurdaydin, MD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Treatment-experienced patients in Central and Eastern Europe – What needs to be done?- Viktor Aster, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

HIV & women’s health: do we have any game changers here?- Mariana Mărdărescu, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Clinical Case Discussion: Switching HIV Therapy- Pavel Khaykin, MD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Clinical considerations in switching antiretroviral therapy- David Jilich, MD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Possible misclassification of HIV transmission between men: results of phylogenetic analysis- Natia Dvali

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Real-life effectiveness of ledipasvir/sofosbuvir regimen and factors associated with retention in care among HIV/HCV co-infected PWID in Ukraine- Tetyana Kyrychenko

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Spontaneous HCV clearance in HCV/HIV coinfected patients from AIDS Center Prague- Viktor Aster

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Epidemiology of HIV in the Baltic countries (Estonia, Latvia, Lithuania)- Saulius Caplinskas

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Critical assessment of the global epidemiology of HCV- Peter Ferenci, MD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018